摘要：Malaria is a highly prevalent parasitic disease in regions with tropical and subtropical climates worldwide. Among the species of
Plasmodium causing human malaria,
P. vivax is the second most prevalent and the most geographically widespread species. A major target of a pre-erythrocytic vaccine is the
P. vivax circumsporozoite protein (
PvCSP). In previous studies, we fused two recombinant proteins representing three allelic variants of
PvCSP (VK210, VK247 and
P. vivax-like) to the mumps virus nucleocapsid protein to enhance immune responses against
PvCSP. The objective of the present study was to evaluate the protective efficacy of these recombinants in mice challenged with transgenic
P. berghei parasites expressing
PvCSP allelic variants. Formulations containing Poly (I:C) or Montanide ISA720 as adjuvants elicited high and long-lasting IgG antibody titers specific to each
PvCSP allelic variant. Immunized mice were challenged with two existing chimeric
P. berghei parasite lines expressing
PvCSP-VK210 and
PvCSP-VK247. We also developed a novel chimeric line expressing the third allelic variant,
PvCSP-
P. vivax-like, as a new murine immunization-challenge model. Our formulations conferred partial protection (significant delay in the time to reach 1% parasitemia) against challenge with the three chimeric parasites. Our results provide insights into the development of a vaccine targeting multiple strains of
P. vivax.
